Literature DB >> 23629473

Targeted therapies: HER2-positive breast cancer-sifting through many good options.

Ian E Krop1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23629473     DOI： 10.1038/nrclinonc.2013.72

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Authors:  D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton
Journal:  N Engl J Med       Date:  2001-03-15       Impact factor: 91.245

3.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Authors:  Charles E Geyer; John Forster; Deborah Lindquist; Stephen Chan; C Gilles Romieu; Tadeusz Pienkowski; Agnieszka Jagiello-Gruszfeld; John Crown; Arlene Chan; Bella Kaufman; Dimosthenis Skarlos; Mario Campone; Neville Davidson; Mark Berger; Cristina Oliva; Stephen D Rubin; Steven Stein; David Cameron
Journal:  N Engl J Med       Date:  2006-12-28       Impact factor: 91.245

4.  Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Authors:  José Baselga; Ian Bradbury; Holger Eidtmann; Serena Di Cosimo; Evandro de Azambuja; Claudia Aura; Henry Gómez; Phuong Dinh; Karine Fauria; Veerle Van Dooren; Gursel Aktan; Aron Goldhirsch; Tsai-Wang Chang; Zsolt Horváth; Maria Coccia-Portugal; Julien Domont; Ling-Min Tseng; Georg Kunz; Joo Hyuk Sohn; Vladimir Semiglazov; Guillermo Lerzo; Marketa Palacova; Volodymyr Probachai; Lajos Pusztai; Michael Untch; Richard D Gelber; Martine Piccart-Gebhart
Journal:  Lancet       Date:  2012-01-17       Impact factor: 79.321

5.  Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors:  Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal:  Lancet Oncol       Date:  2012-01-17       Impact factor: 41.316

6.  Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors:  Sara A Hurvitz; Luc Dirix; Judit Kocsis; Giulia V Bianchi; Janice Lu; Jeferson Vinholes; Ellie Guardino; Chunyan Song; Barbara Tong; Vivian Ng; Yu-Waye Chu; Edith A Perez
Journal:  J Clin Oncol       Date:  2013-02-04       Impact factor: 44.544

7.  Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Authors:  Gunter von Minckwitz; Andreas du Bois; Marcus Schmidt; Nicolai Maass; Tanja Cufer; Felix E de Jongh; Eduard Maartense; Christoph Zielinski; Manfred Kaufmann; Wolfgang Bauer; Klaus H Baumann; Michael R Clemens; Ralph Duerr; Christoph Uleer; Michael Andersson; Robert C Stein; Valentina Nekljudova; Sibylle Loibl
Journal:  J Clin Oncol       Date:  2009-03-16       Impact factor: 44.544

8.  Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.

Authors:  Nancy U Lin; Véronique Diéras; Devchand Paul; Dominique Lossignol; Christos Christodoulou; Hans-Joachim Stemmler; Henri Roché; Minetta C Liu; Richard Greil; Eva Ciruelos; Sibylle Loibl; Stefania Gori; Andrew Wardley; Denise Yardley; Adam Brufsky; Joanne L Blum; Stephen D Rubin; Bernie Dharan; Klaudia Steplewski; Denise Zembryki; Cristina Oliva; Debasish Roychowdhury; Paolo Paoletti; Eric P Winer
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

9.  Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

Authors:  Zhongzhen Guan; Binghe Xu; Michelle L DeSilvio; Zhenzhou Shen; Wichit Arpornwirat; Zhongsheng Tong; Vicharn Lorvidhaya; Zefei Jiang; Junlan Yang; Anatoly Makhson; Wai Lim Leung; Mark W Russo; Beth Newstat; Li Wang; George Chen; Cristina Oliva; Henry Gomez
Journal:  J Clin Oncol       Date:  2013-03-18       Impact factor: 44.544
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.